Intervention Protocol

You have free access to this content

Iodine-131-meta-iodobenzylguanidine therapy for patients with high-risk neuroblastoma

  1. Kathelijne CJM Kraal1,*,
  2. Elvira C van Dalen1,
  3. Godelieve AM Tytgat1,
  4. Berthe L Van Eck-Smit2,
  5. Huib N Caron1

Editorial Group: Cochrane Childhood Cancer Group

Published Online: 28 FEB 2013

DOI: 10.1002/14651858.CD010349

How to Cite

Kraal KCJM, van Dalen EC, Tytgat GAM, Van Eck-Smit BL, Caron HN. Iodine-131-meta-iodobenzylguanidine therapy for patients with high-risk neuroblastoma (Protocol). Cochrane Database of Systematic Reviews 2013, Issue 2. Art. No.: CD010349. DOI: 10.1002/14651858.CD010349.

Author Information

  1. 1

    Emma Children's Hospital / Academic Medical Center, Department of Paediatric Oncology, Amsterdam, Netherlands

  2. 2

    Academic Medical Center, Nuclear Medicine, Amsterdam, Netherlands

*Kathelijne CJM Kraal, Department of Paediatric Oncology, Emma Children's Hospital / Academic Medical Center, PO Box 22660, Amsterdam, 1100 DD, Netherlands.

Publication History

  1. Publication Status: New
  2. Published Online: 28 FEB 2013



Additional references

Bernstein 1992
  • Bernstein ML, Leclerc JM, Bunin G, Brisson L, Robison L, Shuster J, et al. A population-based study of neuroblastoma incidence, survival, and mortality in North America. Journal of Clinical Oncology 1992;10(2):323-9.
Brodeur 1993
  • Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. Journal of Clinical Oncology 1993;11(8):1466-77.
De Kraker 2008
  • De Kraker J, Hoefnagel KA, Verschuur AC, van Eck B, van Santen HM, Caron HN. Iodine-131-metaiodobenzylguanidine as initial induction therapy in stage 4 neuroblastoma patients over 1 year of age. European Journal of Cancer 2008;44(4):551-6.
Grimes 2002
Gurney 1996
Hattner 1984
Higgins 2011
  • Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from
Hoefnagel 1985
  • Hoefnagel CA, Voute PA, de Kraker J, Marcuse HR. Total-body scintigraphy with 131I-meta-iodobenzylguanidine for detection of neuroblastoma. Diagnostic Imaging in Clinical Medicine 1985;54(1):21-7.
Hutchinson 1991
  • Hutchinson RJ, Sisson JC, Miser JS, Zasadny KR, Normolle DP, Shulkin BL, et al. Long-term results of [131I]metaiodobenzylguanidine treatment of refractory advanced neuroblastoma. Journal of Nuclear Biology and Medicine 1991;35(4):237-40.
Klingebiel 1991a
Klingebiel 1991b
  • Klingebiel T, Feine U, Treuner J, Reuland P, Handgretinger R, Niethammer D. Treatment of neuroblastoma with [131I]metaiodobenzylguanidine: long-term results in 25 patients. Journal of Nuclear Biology and Medicine 1991;35(4):216-9.
Kremer 2012
  • Kremer LCM, van Dalen EC, Moher D, Caron HN. Cochrane Childhood Cancer Group. The Cochrane Library 2012, issue 4.
Lashford 1992
  • Lashford LS, Lewis IJ, Fielding SL, Flower MA, Meller S, Kemshead. Phase I/II study of iodine 131 metaiodobenzylguanidine in chemoresistant neuroblastoma: a United Kingdom Children's Cancer Study Group investigation. Journal of Clinical Oncology 1992;10(12):1889-96.
Laupacis 2004
  • Laupacis A, Wells G, Richardson WS, Tugwell P. Users' guides to the medical literature. V. How to use an article about prognosis. Evidence-Based Medicine Working Group. The Journal of the American Medical Association. 1994;272(3):234-7.
Leung 1997
  • Leung A, Shapiro B, Hattner R, Kim E, Ghazzar N. Specificity of radioiodinated MIBG for neural crest tumors in childhood. Journal of Nuclear Medicine 1997;38(9):1352-7.
Lumbroso 1991
  • Lumbroso J, Hartmann O, Schlumberger M. Therapeutic use of [131I]metaiodobenzylguanidine in neuroblastoma: a phase II study in 26 patients. "Societe Francaise d'Oncologie Pediatrique" and Nuclear Medicine Co-investigators. Journal of Nuclear Biology and Medicine 1991;35(4):220-3.
Matthay 1998
  • Matthay KK, DeSantes K, Hasegawa B, Huberty J, Hattner RS, Ablin A. Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma. Journal of Clinical Oncology 1998;16(1):229-36.
Matthay 1999
  • Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. New England Journal of Medicine 1999;341(16):1165-73.
Matthay 2001
  • Matthay KK, Panina C, Huberty J, Price D, Glidden DV, Tang HR, et al. Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with (131)I-MIBG. Journal of Nuclear Medicine 2001;42(11):1713-21.
Matthay 2007
  • Matthay KK, Yanik G, Messina J, Quach A, Huberty J, Cheng SC, et al. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma. Journal of Clinical Oncology 2007;25(9):1054-60.
Matthay 2009
  • Matthay KK, Reynolds CP, Seeger RC, Shimada H, Adkins ES, Haas-Kogan D, et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic Acid: A Children's Oncology Group Study. Journal of Clinical Oncology 2009;27(7):1007-13.
Parmar 1998
Review Manager 2011 [Computer program]
  • The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
Shimada 1995
  • Shimada H, Stram DO, Chatten J, Joshi VV, Hachitanda Y, Brodeur GM, et al. Identification of subsets of neuroblastomas by combined histopathologic and N-myc analysis. Journal National Cancer Institute 1995;87(19):1470-6.
Shimada 1999
Simon 2011
Suc 1996
Voute 1991
  • Voute PA, Hoefnagel CA, de Kraker KJ, Valdes OR, Bakker DJ, van de Kleij AJ. Results of treatment with 131 I-metaiodobenzylguanidine (131 I-MIBG) in patients with neuroblastoma. Future prospects of zetotherapy. Progress in Clinical and Biological Research 1991;366:439-45.
Yalcin 2010
  • Yalçin B, Kremer LC, Caron HN, van Dalen EC. High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma. Cochrane Database of Systematic Reviews 2010, Issue 5. [DOI: 10.1002/14651858.CD006301.pub2]